Following disappointing clinical trial results for AK006, Allakos will cut its workforce down to under 20 employees as it ...
Emerson Electric Company to acquire Aspen Technology shares not already owned by them in a $7.2 billion deal, valuing shares ...
Naporafenib is Erasca’s main candidate, and it has Fast Track status for NRASm melanoma. See why I rate ERAS stock as a buy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback